A Single-center, Double-blind Placebo-controlled Parallel Group Phase II Study of the Efficacy and Safety of Rilonacept in Subjects With Cold Contact Urticaria (CCU)

Trial Profile

A Single-center, Double-blind Placebo-controlled Parallel Group Phase II Study of the Efficacy and Safety of Rilonacept in Subjects With Cold Contact Urticaria (CCU)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Rilonacept (Primary)
  • Indications Urticaria
  • Focus Therapeutic Use
  • Acronyms Cures
  • Most Recent Events

    • 05 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
    • 05 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
    • 28 Jan 2016 Planned End Date changed from 1 May 2015 to 1 Apr 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top